{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:57:13Z","timestamp":1790647033222,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12149-026-02236-7","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T06:56:17Z","timestamp":1779519377000},"page":"1210-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline PSMA-ligand PET\/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Baptiste","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9ane","family":"Dr\u00e9ano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Neveu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Estrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Crouzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Broyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Bouvry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Le Jeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Faudemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Farce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"3","key":"2236_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2236_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27(2):327\u201333.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"2236_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u201303.","journal-title":"N Engl J Med"},{"issue":"10276","key":"2236_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u201304.","journal-title":"Lancet"},{"issue":"7","key":"2236_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","volume":"26","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, et al. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol. 2025;26(7):948\u201359.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2236_CR6","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","volume":"48","author":"K Michalski","year":"2021","unstructured":"Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, et al. Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48(6):2024\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2236_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(11):1389\u201397.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2236_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","volume":"52","author":"T Telli","year":"2025","unstructured":"Telli T, Lopes L, Karpinski M, Pabst KM, Gr\u00fcnwald V, Shi K, Hadaschik B, et al. Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. Eur J Nucl Med Mol Imaging. 2025;52(9):3199\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2236_CR9","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2):e233460.","journal-title":"Radiology"},{"key":"2236_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1538507","volume":"12","author":"H Peslier","year":"2025","unstructured":"Peslier H, Seegers V, Dufour PA. Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer. Front Med. 2025;12:1538507.","journal-title":"Front Med"},{"issue":"4","key":"2236_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2236_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ajco.14174","volume":"21","author":"NXY Koh","year":"2025","unstructured":"Koh NXY, Chua WM, Lam WW, Tong AK, Kanesvaran R, Wong ASC, et al. Prognostic [68Ga]Ga-PSMA-11 PET biomarkers for [177Lu]Lu-PSMA radioligand therapy in metastatic castrate-resistant prostate cancer (Asian population study). Asia Pac J Clin Oncol. 2025;21(4):399\u201306.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"2236_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","volume":"86","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, et al. Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA-617 in the phase 3 VISION Trial. Eur Urol. 2024;86(6):552\u201362.","journal-title":"Eur Urol"},{"issue":"12","key":"2236_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2236_CR15","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, H\u00fcttmann T, Seitz AK, K\u00fcbler H, Serfling SE, Schl\u00f6telburg W, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50(11):3465\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2236_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","volume":"26","author":"R Eisazadeh","year":"2024","unstructured":"Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, Hehenwarter L, Rendl G, Gampenrieder S, et al. Pre-treatment 68 Ga-PSMA-11 PET\/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival. Mol Imaging Biol. 2024;26(2):360\u201369.","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"2236_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307826","volume":"19","author":"T Zhang","year":"2024","unstructured":"Zhang T, Li W, Wei H, Huang Z, Yang J, Zeng H, et al. Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. PLoS One. 2024;19(12):e0307826.","journal-title":"PLoS One"},{"issue":"1","key":"2236_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.124.268167","volume":"66","author":"RA Demirci","year":"2025","unstructured":"Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, et al. PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings. J Nucl Med. 2025;66(1):47\u201353.","journal-title":"J Nucl Med"},{"issue":"8","key":"2236_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2967\/jnumed.122.265346","volume":"64","author":"A Karimzadeh","year":"2023","unstructured":"Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, et al. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. J Nucl Med. 2023;64(8):1252\u201358.","journal-title":"J Nucl Med"},{"issue":"1","key":"2236_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, B\u00f6gemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2236_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"1","key":"2236_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12894-022-01050-3","volume":"22","author":"R Wrenger","year":"2022","unstructured":"Wrenger R, J\u00fcptner M, Marx M, Zhao Y, Zuhayra M, Caliebe A, et al. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy. BMC Urol. 2022;22(1):96.","journal-title":"BMC Urol"},{"issue":"13","key":"2236_CR23","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Bundschuh RA, Weinzierl FX, Serfling SE, Kosmala A, Seitz AK, et al. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease. Eur J Nucl Med Mol Imaging. 2022;49(13):4727\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4_suppl","key":"2236_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2024.42.4_suppl.157","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, Wulff-Burchfield EM, Abbasi S, Narang A, Dal E, Donald J, et al. PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment. J Clin Oncol. 2024;42(4_suppl):157\u2013157.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2236_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.1464-410X.2008.07873.x","volume":"102","author":"A Sella","year":"2008","unstructured":"Sella A, Sternberg CN, Skoneczna I, Kovel S. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int. 2008;102(11):1607\u201309.","journal-title":"BJU Int"},{"issue":"2","key":"2236_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clgc.2016.07.026","volume":"15","author":"Y Ueda","year":"2017","unstructured":"Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, et al. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017;15(2):320\u201325.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2236_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clgc.2014.06.010","volume":"13","author":"SL Burgio","year":"2015","unstructured":"Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39\u201343.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2236_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, Spielhofer N, Skawran S, Heimer J, et al. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024;14(1):36.","journal-title":"EJNMMI Res"},{"key":"2236_CR29","doi-asserted-by":"publisher","first-page":"1382582","DOI":"10.3389\/fonc.2024.1382582","volume":"14","author":"S Yadav","year":"2024","unstructured":"Yadav S, Kim ST, Tuchayi AM, Jiang F, Morley A, Saelee R, et al. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection. Front Oncol. 2024;14:1382582.","journal-title":"Front Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02236-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:38Z","timestamp":1790643998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02236-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02236-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}